Literature DB >> 30126755

Neurological Complications of the Treatment of Pediatric Neoplastic Disorders.

Lisa R Sun1, Stacy Cooper2.   

Abstract

Neurological complications resulting from childhood cancer treatments are common. Treatment for childhood neoplastic disorders is often multimodal and may include procedures, cranial irradiation, chemotherapy, transplant, and immunotherapy, each of which carries distinct neurological risks. Procedures, such as lumbar punctures, are commonly used in this population for diagnostic purposes as well as intrathecal medication administration. Surgery is associated with an array of potential neurological complications, with posterior fossa syndrome being a common cause of morbidity in pediatric brain tumor patients after neurosurgical resection. Cranial irradiation can cause late neurological sequelae such as stroke, cerebral vasculopathy, secondary malignancy, and cognitive dysfunction. Neurotoxic effects of chemotherapeutic agents are common and include neuropathy, coagulopathy causing stroke or cerebral sinovenous thrombosis, encephalopathy, seizures, cerebellar dysfunction, myelopathy, and neuropsychologic difficulties. Hematopoietic stem cell transplant has a high risk of neurological complications including central nervous system infection, seizures, and stroke. Immunotherapies, including chimeric antigen receptor-modified T-cells (CAR T-cells) and immune checkpoint inhibitors, are emerging as potentially effective strategies to treat some types of childhood cancer, but may carry with them substantial neurotoxicity which is just beginning to be recognized and studied. With evolving treatment protocols, childhood cancer survivorship is increasing, and the role of the neurologist in managing both the acute and chronic neurological consequences of treatment is becoming more important. Prevention, early recognition, and treatment of therapy-associated neurotoxicity are imperative to ensuring children can remain on the most effective therapeutic regimens and to improve the neurological function and quality of life of childhood cancer survivors.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Chemotherapy; Childhood cancer; Immunotherapy; Neurological complications; Neurotoxicity; Radiation

Mesh:

Year:  2018        PMID: 30126755     DOI: 10.1016/j.pediatrneurol.2018.05.011

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

Review 1.  Saving normal tissues - a goal for the ages.

Authors:  Angela M Groves; Jacqueline P Williams
Journal:  Int J Radiat Biol       Date:  2019-03-29       Impact factor: 2.694

2.  Improved prediction of postoperative pediatric cerebellar mutism syndrome using an artificial neural network.

Authors:  Jai Sidpra; Adam P Marcus; Ulrike Löbel; Sebastian M Toescu; Derek Yecies; Gerald Grant; Kristen Yeom; David M Mirsky; Hani J Marcus; Kristian Aquilina; Kshitij Mankad
Journal:  Neurooncol Adv       Date:  2022-01-10

Review 3.  Review: Neurological Complications From Therapies for Pediatric Brain Tumors.

Authors:  Thien Nguyen; Sabine Mueller; Fatema Malbari
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

4.  Exploring Trends in Neuromonitoring Use in a General Pediatric ICU: The Need for Standardized Guidance.

Authors:  Nathan Chang; Lindsey Rasmussen
Journal:  Children (Basel)       Date:  2022-06-22

5.  Child Neglect by Any Other Name.

Authors:  E Steve Roach
Journal:  Pediatr Neurol       Date:  2020-09-17       Impact factor: 3.372

Review 6.  Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage.

Authors:  Iside Alessi; Anna Maria Caroleo; Luca de Palma; Angela Mastronuzzi; Stefano Pro; Giovanna Stefania Colafati; Alessandra Boni; Nicoletta Della Vecchia; Margherita Velardi; Melania Evangelisti; Alessia Carboni; Andrea Carai; Luciana Vinti; Massimiliano Valeriani; Antonino Reale; Pasquale Parisi; Umberto Raucci
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.